What Is BSX Fair Value?
Boston Scientific (BSX) fair value estimate using multiple valuation models, updated daily.
As of August 29, 2026, Boston Scientific (BSX) has a composite fair value estimate of $37.58 based on four valuation models: DCF (41% weight), Graham Number (29% weight), PEG (29% weight), and DDM (0% weight). The current market price is $46.84, suggesting the stock is overvalued by 19.8%.
Data as of August 29, 2026 (today)
Composite Fair Value
Overvalued3 of 4 models$37.58
vs. current price of $46.84(-19.8%)
How Is BSX Fair Value Calculated?
Four independent models estimate what BSX is worth. Each uses different inputs and assumptions. The composite blends them by weight.
BSX Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
41% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$35.79
-23.6%Overvalued
Inputs used
DDM (Dividend Discount Model)
0% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
N/A
This stock does not pay a dividend, so the DDM cannot be applied. The composite adjusts by redistributing this weight to the other models.
BSX Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
29% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$35.79
-23.6%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
29% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$33.04
-29.5%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $46.84 is 23.6% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $2.60B | $2.43B |
| Year 2 | $2.75B | $2.40B |
| Year 3 | $2.91B | $2.38B |
| Year 4 | $3.09B | $2.35B |
| Year 5 | $3.27B | $2.33B |
| Year 6 | $3.47B | $2.30B |
| Year 7 | $3.67B | $2.28B |
| Year 8 | $3.89B | $2.26B |
| Year 9 | $4.12B | $2.23B |
| Year 10 | $4.37B | $2.21B |
| Terminal Value | $98.58B | $49.94B |
What Are BSX's Key Financial Metrics?
Earnings & Growth
Current Price
$46.84
EPS (TTM)
$2.48
Forward P/E
13.6
Profit Margin
17.5%
Cash & Balance Sheet
Free Cash Flow
2.5B
EBITDA
5.7B
Book Value
$17.23
Total Debt
12.6B
What Do Analysts Say About BSX?
Low
$44.00
Average
$62.69
High
$94.00
Upside
+33.8%
BSX Fair Value FAQ
What is the fair value of BSX?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), BSX's estimated fair value is $37.58. The stock is currently trading at $46.84, which makes it overvalued by our analysis.
How is BSX's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is BSX overvalued or undervalued?
Based on our analysis, BSX is overvalued. The current price of $46.84 is 19.8% above our estimated fair value of $37.58.
What do Wall Street analysts say about BSX?
29 analysts cover Boston Scientific with a consensus rating of "Buy." The average price target is $62.69, ranging from $44.00 to $94.00. This implies 33.8% upside from the current price.